TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study

Company: Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the second round of dosing for all nine study participants in the second arm of its human pilot study #2 has been completed. The company anticipates completion of the final arm of the study, GLP-1-H24-2, in July. A three-arm, crossover investigation that compares three 7 mg semaglutide dose formulations, the study evaluates three doses: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsule; and for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. The study is designed to measure tolerability and side effects as well as semaglutide and blood glucose levels. Rybelsus (semaglutide) is the only GLP-1 drug approved by the FDA for oral dosingto treat diabetes and weight loss. “Blood samples will be taken multiple times during the first 10 hours post dosing,” the company stated in the press release. “A final blood draw will be taken 24 hours after dosing, and a standardized meal will be fed to the test subjects at a point in time after dosing. Nine healthy subjects are expected to be dosed with each test article with roughly a 30-day ‘washout’ interval between each dosing visit.

To view the full press release, visit https://ibn.fm/TALlT

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 43 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

Los Angeles, CA
310.299.1717 Office

TinyGems is powered by IBN

Contact us: (310) 299-1717